Ransom Advisory Ltd Makes New $536,000 Investment in Pfizer Inc. $PFE

Key Points

• Ransom Advisory Ltd has acquired a new stake in Pfizer Inc., totaling 21,133 shares valued at approximately $536,000, during the first quarter.
• Recent analyst reports show a mixed outlook on Pfizer's stock, with Bank of America raising its price target to $28.00 while HSBC lowered its target to $26.00, reflecting a consensus rating of "Hold".
• Pfizer recently declared a quarterly dividend of $0.43 per share, which equates to an annual yield of 7.0% with a high payout ratio of 91.49%.

Ransom Advisory Ltd purchased a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 21,133 shares of the biopharmaceutical company's stock, valued at approximately $536,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. Pacer Advisors Inc. boosted its stake in Pfizer by 856.8% during the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock worth $508,164,000 after purchasing an additional 17,957,928 shares during the last quarter. Amundi lifted its stake in shares of Pfizer by 43.4% in the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock worth $1,265,277,000 after buying an additional 15,758,846 shares in the last quarter. Nuveen LLC purchased a new position in shares of Pfizer in the first quarter worth about $389,861,000. Starboard Value LP purchased a new position in shares of Pfizer in the fourth quarter worth about $407,730,000. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Pfizer by 51.9% in the first quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company's stock worth $670,407,000 after buying an additional 9,041,990 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Trading Up 1.1%

PFE traded up $0.27 on Thursday, hitting $24.84. The company had a trading volume of 36,770,116 shares, compared to its average volume of 34,782,688. The company's fifty day moving average price is $24.82 and its 200 day moving average price is $24.32. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The firm has a market cap of $141.23 billion, a P/E ratio of 13.21, a PEG ratio of 0.87 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer's revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.9%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer's dividend payout ratio (DPR) is 91.49%.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. HSBC decreased their price target on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research note on Monday, May 19th. Jefferies Financial Group raised their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research note on Wednesday, May 21st. Citigroup raised their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Bank of America upped their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Finally, Berenberg Bank dropped their price objective on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.